Crescita Therapeutics (TSX:CTX) Ending Cash Position: C$8.71 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CTX Crescita Therapeutics Inc TSX:CTX
20 GF Score
Price C$0.79
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Ending Cash Position?

Crescita Therapeutics TSX:CTX 20 Ending Cash Position is C$8.71 Mil as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100. The stock has 5 warning signs investors should review.

Crescita Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was C$8.71 Mil.

Crescita Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 (C$8.31 Mil) to Dec. 2025 (C$8.58 Mil) and increased from Dec. 2025 (C$8.58 Mil) to Mar. 2026 (C$8.71 Mil).

Crescita Therapeutics's annual Ending Cash Position declined from Dec. 2023 (C$9.39 Mil) to Dec. 2024 (C$9.27 Mil) and declined from Dec. 2024 (C$9.27 Mil) to Dec. 2025 (C$8.58 Mil).

Crescita Therapeutics Ending Cash Position Related Terms

Crescita Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Ending Cash Position Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.33 8.24 9.39 9.27 8.58

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.54 8.18 8.31 8.58 8.71
TSX:CTX
20GF Score
Crescita Therapeutics Inc TSX:CTX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Crescita Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9.273+-0.696
=8.58

Crescita Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.577+0.133
=8.71

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of C$8.71 Mil mean?
Crescita Therapeutics (TSX:CTX) has a Ending Cash Position of C$8.71 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Ending Cash Position too high?
Crescita Therapeutics' current Ending Cash Position is C$8.71 Mil. Overall, Crescita Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Ending Cash Position compare to ZTS?
Crescita Therapeutics' Ending Cash Position of C$8.71 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Ending Cash Position is C$8.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Crescita Therapeutics (TSX:CTX) has a current Ending Cash Position of C$8.71 Mil. The current Ending Cash Position is C$8.71 Mil. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Ending Cash Position is C$8.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score

Get the complete analysis for TSX:CTX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.79
Price